About PharmaFlo

Our vision of an environmentally sustainable installation that would allow the optimal production and extraction of secondary plant metabolites came to life with the construction of our very first installation in Gatineau, Quebec. Our installation now boasts facilities that contribute to the development of plant-based pharmaceutical drugs for diseases such as Parkinson’s disease, epilepsy, and chronic pain.

An industry leader in pharmaceutical plant-based compounds driven by data research and development.

Our senior team members have combined expertise from industries ranging from agribusiness to cannabis production. Having led medium to large-scale initiatives in a diverse range of industries, our team members have the insight and experience to enforce PharmaFlo’s vision of highly efficient and sustainable agronomy, while creating long-term partnerships within the community and pharmaceutical industry.

Our management team


Louis-Alexandre Morin
Chief Executive Officer
Pascal Nadeau
Chief Strategy Officer and Market Development
Josiève Brissette-Bélanger
Chief Financial Officer
Louis Morin
Chairman
Marc Bélanger
Board Member
Patrick Filice
Board Member
Pat Manno
Board Member
Corinne Claveau
Financial Controller
Pharmaflo Louis Alexandre Morin
Louis-Alexandre Morin
Chief Executive Officer
Pharmaflo Pascal Nadeau
Pascal Nadeau
Chief Strategy Officer and Market Development
Pharmaflo Josieve Brissette
Josiève Brissette-Bélanger
Chief Financial Officer
Pharmaflo Louis Morin
Louis Morin
Chairman
Pharmaflo Marc Belanger
Marc Bélanger
Board Member
Pharmaflo Patrick Filice
Patrick Filice
Board Member
Pharmaflo Pat Manno
Pat Manno
Board Member
Image
Corinne Claveau
Financial Controller

Our growers team


Image
Erika Lamoureux
Master Grower
With over 7 years' experience in the cannabis field, a diploma from the Horticultural Industries program, and an unwavering passion for what she does, Erika is a formidable and distinguished force within PharmaFlo. Erika's passion for her work goes beyond her job description. She is an advocate of responsible and sustainable cannabis cultivation, promoting ethical and environmentally friendly practices within the industry. Her commitment to her values is a model for the field, and these are also passed on within the team she oversees, driving positive change and promoting sustainability. In addition, Erika's willingness to share her knowledge and mentor talent help foster a culture of continuous learning and innovation. Her mentoring has enabled many of her team members to develop their skills and make their own contribution to the cannabis industry.
Image
Jimmy Racine
Tissue Culture and Biosafety Specialist
Jimmy is a respected presence in the cannabis industry, known for his career marked by dedication and a keen interest in cannabis. His journey into this field began at a young age, driven by a genuine fascination with different cannabis strains and their potential. Over the years, Jimmy has consistently aimed for excellence, making strides to advance the industry and uphold quality standards. Notably, Jimmy is also an approachable mentor who willingly shares his knowledge with his team. He contributes to fostering a sense of camaraderie and learning among his colleagues. Jimmy's ongoing passion for the cannabis industry serves as an inspiration to his peers. His commitment to responsible practices, sustainability, and research and development has helped the industry adapt to changing regulations and consumer preferences. Furthermore, his mentorship has contributed to the development of a new generation of professionals who are ready to continue pushing the industry forward with innovation.
Image
Dany Hallé
Head of Quality Assurance
Dany Hallé has a solid background in the scientific field, counting 20 years of dedicated work in animal health. His academic career began with an Animal Health Technician diploma, laying the foundations for his in-depth understanding of laboratory research and practical biotechnology operations. He then focused his studies on pharmaceutical and biotechnology quality assurance, earning an AEC at Collège Gerald Godin. During his seven years' experience in quality assurance in the pharmaceutical industry, Dany played a key role in developing quality control procedures, managing regulatory compliance audits and monitoring the application of good manufacturing practices. Finally, with 5 years' experience in quality assurance in the cannabis sector, Dany has demonstrated his ability to ensure compliance with quality and safety standards. He has also been responsible for managing documentation systems and implementing measures to meet specific regulatory requirements in this fast-growing industry.
In 2022, PharmaFlo received a $10M loan from the Ministry of Economy and Innovation, in recognition of our pioneering efforts in energy conservation, recycling, and sustainable cultivation techniques for indoor farming, as well as our unwavering commitment to research and development.
pharmaflo production

Our facility

Our installations include state-of-the-art research and production facilities, and an extraction laboratory that meets the highest pharmaceutical standards. Demand for plant-based extracts has undeniably exploded in recent years due to increased pharmaceutical testing and research in the area of plant-based or partially plant-based drugs. PharmaFlo is well positioned to provide international customers with pharmaceutical grade plant-based extracts.

Innovation through sustainability

Sustainability

Sustainability is our core value. Our vertical cultivation systems maximize production space and efficiency and are paving the way for the future of agribusiness and cultivation practices in general. We believe our technology represents an innovative opportunity for Canada to become a worldwide leader in sustainable, local food production.

Scientific Innovation

Necessity breeds innovation: our devotion to optimal cultivation and extraction practices means our experts are constantly on the lookout for opportunities to refine and improve our proprietary methods and processes.

Leadership

We’re spreading the word and helping producers in various industries convert and optimize their cultivation practices. We believe in contributing to generational wealth by sharing our knowledge of technology and visionary ideas with others.

Accountability and responsibility

Our technologies and practices offer enormous potential for discovering and developing life-changing medical alternatives for individuals suffering from a multitude of diseases. In everything we do, we strive to implement best practices to support the further development of plant-based medicine, which could have huge positive repercussions in many areas of medicine.

Health

The high-quality compounds we deliver to our pharmaceutical clients allow research and development that could potentially change the lives of people affected by various diseases and medical conditions. The benefits of plant-based drugs are increasingly recognized and deliver great promise for more efficient treatment of various medical conditions, lower side effects, and reduced consumer costs across all healthcare fields.

Milestones

January 2019Architectural and engineering work begins at PharmaFlo’s location in Gatineau.
June 2019First round of funding.
August 2020Construction of the GMP-compliant facility begins.
June 2021End of first phase of construction and second phase of funding.
September 2021PharmaFlo invests an additional $25M specialized equipment for the construction of its state-of-the-art facility.
March 2022End of third phase of funding.
June 2022Production of evidence package for Health Canada.
July 2022PharmFlo receives a $10M loan from Investissement Québec in partnership with the Ministry of Economy and Innovation. Additionally, PharmaFlo receives a $4M subsidy from Hydro-Québec for its facility’s energy cost savings, and a $1.5M subsidy from the TEQ for its energy recuperation system.
December 2022Construction of the facility is finalized and commissioning of the systems is launched.
February 2023PharrmaFlo receives its cultivation and sales license from Health Canada, opening the door to international export.
March 2023PharmaFlo concludes an agreement with a university in Ontario for Research and Development of its genetic bank.
End of 2023EU GMP certification is underway and an audit of international authorities is to be completed by the third quarter of 2023.

    Social responsibility

    PharmaFlo is proud to encourage local entrepreneurs and is committed, whenever possible, to prioritizing local economies. From locally sourced technologies and manufacturers to the command of Canadian experts, PharmaFlo is contributing to the development of a local and nationwide initiative for sustainable agronomy within the pharmaceutical industry.

    Initiatives such as local employment and limiting unpleasant emissions for nearby residents are crucial in creating lasting partnerships with communities. At PharmaFlo, we believe that sustainability is rooted in technology, but also in people.